Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Extracellular albumin covalently sequesters selenocompounds and determines cytotoxicity

  • Zheng, Wenyi
  • Boada, Roberto|||0000-0003-4857-8402
  • He, Riu
  • Xiao, Tingting|||0000-0001-9818-8627
  • Ye, Fei|||0000-0002-1679-1316
  • Simonelli, Laura|||0000-0001-5331-0633
  • Valiente, Manuel|||0000-0003-0766-9922
  • Zhao, Ying
  • Hassan, Moustapha
Selenocompounds (SeCs) are well-known nutrients and promising candidates for cancer therapy; however, treatment efficacy is very heterogeneous and the mechanism of action is not fully understood. Several SeCs have been reported to have albumin-binding ability, which is an important factor in determining the treatment efficacy of drugs. In the present investigation, we hypothesized that extracellular albumin might orchestrate SeCs efficacy. Four SeCs representing distinct categories were selected to investigate their cytotoxicity, cellular uptake, and species transformation. Concomitant treatment of albumin greatly decreased cytotoxicity and cellular uptake of SeCs. Using both X-ray absorption spectroscopy and hyphenated mass spectrometry, we confirmed the formation of macromolecular conjugates between SeCs and albumin. Although the conjugate was still internalized, possibly via albumin scavenger receptors expressed on the cell surface, the uptake was strongly inhibited by excess albumin. In summary, the present investigation established the importance of extracellular albumin binding in determining SeCs cytotoxicity. Due to the fact that albumin content is higher in humans and animals than in cell cultures, and varies among many patient categories, our results are believed to have high translational impact and clinical implications.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A general covalent binding model between cytotoxic selenocompounds and albumin revealed by mass spectrometry and X-ray absorption spectroscopy

  • Zheng, Wenyi
  • He, Rui
  • Boada, Roberto|||0000-0003-4857-8402
  • Subirana, Maria Angels
  • Ginman, Tobias
  • Ottosson, Håkan
  • Valiente, Manuel|||0000-0003-0766-9922
  • Zhao, Ying
  • Hassan, Moustapha
Selenocompounds (SeCs) are promising therapeutic agents for a wide range of diseases including cancer. The treatment results are heterogeneous and dependent on both the chemical species and the concentration of SeCs. Moreover, the mechanisms of action are poorly revealed, which most probably is due to the detection methods where the quantification is based on the total selenium as an element. To understand the mechanisms underlying the heterogeneous cytotoxicity of SeCs and to determine their pharmacokinetics, we investigated selenium speciation of six SeCs representing different categories using liquid chromatography-mass spectrometry (LC-MS) and X-ray absorption spectroscopy (XAS) and the cytotoxicity using leukemic cells. SeCs cytotoxicity was correlated with albumin binding degree as revealed by LC-MS and XAS. Further analysis corroborated the covalent binding between selenol intermediates of SeCs and albumin thiols. On basis of the Se-S model, pharmacokinetic properties of four SeCs were for the first time profiled. In summary, we have shown that cytotoxic SeCs could spontaneously transform into selenol intermediates that immediately react with albumin thiols through Se-S bond. The heterogeneous albumin binding degree may predict the variability in cytotoxicity. The present knowledge will also guide further kinetic and mechanistic investigations in both experimental and clinical settings.
Dipòsit Digital de Documents de la UAB
Publication Artículo preliminar (WorkingPaper)

New Selenium-based nanocapsules to treat Breast Cancer, NEOSETAC

  • Sánchez-Martín, María-Jesús|||0000-0003-1678-6055
  • Valiente, Manuel|||0000-0003-0766-9922
Breast cancer is the most common cancers in women, it comprises of 10.4% of all the cancer incidences among women, causing 411 093 deaths per year overall the world. The complexity of breast cancer makes it a big challenge for successful treatment. Its treatment is dependent on disease stage, histologic and molecular subtypes and menopausal status. Surgery (mastectomy or breast-conserving surgery with or without lymph node dissection) and radiotherapy play an important role in early breast cancer: systemic therapy may be used for almost all women and is the predominant treatment for those with advanced disease. Targeted treatment of breast cancer remains an important goal for the future, but to date this has been relatively hard to achieve due to the complexity and variability of the disease.